Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.51)
# 275
Out of 5,050 analysts
126
Total ratings
51.75%
Success rate
24.77%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBLG FibroBiologics | Maintains: Buy | $10 → $5 | $0.35 | +1,318.84% | 7 | Nov 5, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $13.25 | +96.23% | 11 | Oct 31, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $42 → $52 | $38.02 | +36.77% | 12 | Oct 30, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $8 → $6 | $2.04 | +194.12% | 2 | Oct 30, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $33.61 | +30.91% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $68.25 | +28.94% | 2 | Oct 20, 2025 | |
| IMUX Immunic | Reiterates: Buy | $10 | $0.72 | +1,291.59% | 5 | Sep 26, 2025 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $4.32 | +594.44% | 7 | Sep 23, 2025 | |
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $17.63 | -71.64% | 5 | Aug 18, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $5.92 | +102.70% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $4.61 | +247.07% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $22.97 | +143.80% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.00 | +300.00% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.59 | +78.89% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.69 | +113.22% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $12.20 | +162.30% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $10.50 | +242.86% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $449.13 | -93.77% | 1 | Aug 22, 2023 |
FibroBiologics
Nov 5, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $0.35
Upside: +1,318.84%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $13.25
Upside: +96.23%
Mineralys Therapeutics
Oct 30, 2025
Maintains: Buy
Price Target: $42 → $52
Current: $38.02
Upside: +36.77%
Akebia Therapeutics
Oct 30, 2025
Maintains: Buy
Price Target: $8 → $6
Current: $2.04
Upside: +194.12%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $33.61
Upside: +30.91%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $68.25
Upside: +28.94%
Immunic
Sep 26, 2025
Reiterates: Buy
Price Target: $10
Current: $0.72
Upside: +1,291.59%
Adverum Biotechnologies
Sep 23, 2025
Reiterates: Buy
Price Target: $30
Current: $4.32
Upside: +594.44%
Kodiak Sciences
Aug 18, 2025
Maintains: Neutral
Price Target: $3 → $5
Current: $17.63
Upside: -71.64%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $5.92
Upside: +102.70%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $4.61
Upside: +247.07%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $22.97
Upside: +143.80%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.00
Upside: +300.00%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.59
Upside: +78.89%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $4.69
Upside: +113.22%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $12.20
Upside: +162.30%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $10.50
Upside: +242.86%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $449.13
Upside: -93.77%